CCM
CEROW

Context Capital Management’s CERo Therapeutics Warrants CEROW Stock Holding History

Context Capital Management’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-122,013
Closed -$1.62K – 329
2025
Q3 		$1.62K Hold
122,013
– – ﹤0.01% 265
2025
Q2 		$2.9K Hold
122,013
– – ﹤0.01% 241
2025
Q1 		$1.77K Hold
122,013
– – ﹤0.01% 201
2024
Q4 		$1.01K Hold
122,013
– – ﹤0.01% 225
2024
Q3 		$622 Hold
122,013
– – ﹤0.01% 280
2024
Q2 		$2.45K Hold
122,013
– – ﹤0.01% 210
2024
Q1 		$8.32K Sell
122,013
-77,987
-39% -$4.74K ﹤0.01% 203
2023
Q4 		$5.5K Hold
200,000
– – ﹤0.01% 205
2023
Q3 		$14K Hold
200,000
– – ﹤0.01% 190
2023
Q2 		$12K Hold
200,000
– – ﹤0.01% 198
2023
Q1 		$8K Hold
200,000
– – ﹤0.01% 272
2022
Q4 		$9K Hold
200,000
– – ﹤0.01% 329
2022
Q3 		$16K Hold
200,000
– – ﹤0.01% 432
2022
Q2 		$20K Hold
200,000
– – ﹤0.01% 468
2022
Q1 		$44K Buy
+200,000
New +$74.3K ﹤0.01% 507

Other funds holding CEROW

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Context Capital Management's CEROW Position: Q4 2025 in Review

Context Capital Management sold out of CERo Therapeutics Warrants (CEROW) in Q4 2025, closing a stake of 122,013 shares — an estimated $1.62K sold.

Context Capital Management first reported a position in CEROW in Q1 2022 and held it in 15 quarters. The position peaked at $44K in Q1 2022. 1 fund tracked by Wall St. Rank holds CEROW as of Q4 2025.

  • Context Capital Management reported no remaining CERo Therapeutics Warrants position as of Q4 2025 after selling out during the quarter.
  • Context Capital Management sold 122,013 CERo Therapeutics Warrants shares in Q4 2025, an estimated $1.62K.
  • Context Capital Management first reported a position in CERo Therapeutics Warrants in Q1 2022 and held it in 15 quarters.
  • Context Capital Management's CERo Therapeutics Warrants position peaked at $44K in Q1 2022.
  • 1 fund tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q4 2025.

Based on Context Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.